| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: Galvanize Therapeutics |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: AstraZeneca/MedImmune |
| Recipient: You |
| Company: GSK |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Taiho Oncology |
| Recipient: You |
| Company: Novocure |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Picture Health |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Trovagene |
| Recipient: Your Institution |
| Company: Eisai |
| Recipient: Your Institution |
| Company: OncoPlex Diagnostics |
| Recipient: Your Institution |
| Company: Alkermes |
| Recipient: Your Institution |
| Company: NantOmics |
| Recipient: Your Institution |
| Company: Genoptix |
| Recipient: Your Institution |
| Company: Altor BioScience |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Atreca |
| Recipient: Your Institution |
| Company: Heat Biologics |
| Recipient: Your Institution |
| Company: Leap Therapeutics |
| Recipient: Your Institution |
| Company: RSIP Vision |
| Recipient: Your Institution |
| Company: GlaxoSmithKline |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|